Tag: FDA warnings
-
New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With “joint pain that can be severe and disabling”
Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced…
-
Onglyza Update: FDA May Require A New Warning About Possible Increased Risk Of Heart Failure For Diabetes Drugs Onglyza And Kombiglyze XR
April 2015 FDA Advisory Committee Voted For An Onglyza Drug Label Change About Side Effects Risks, With One Panelist Voting Of An Onglyza Recall (Posted by Tom Lamb at DrugInjuryWatch.com) As previewed…
-
Invokana / Farxiga / Jardiance: New Medical Study Finds A History Of Diabetic Ketoacidosis Events Is Associated With Increased Risk of Death
This Ketoacidosis Side Effect For These New Diabetes Medicines Was The Subject Of A May 2015 FDA Drug Safety Warning Which Was, Perhaps, Not Strong Enough About Dangers (Posted by Tom Lamb at…
-
May 2015 Diabetes Drugs – Ketoacidosis Link Warning By FDA Covers Invokana, Farxiga, And Jardiance, With Label Changes Possible
Case Reports Of These Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Causing Diabetic Ketoacidosis (DKA) Presented At Recent Medical Meeting (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link Between DKA &…
-
Long-Term Combined Plavix – Effient Use May Be Associated With An Increased Overall Risk Of Non-Cardiovascular Death Compared To Shorter Therapy Period
FDA Drug Safety Communication Issued In November 2014 About The Dual Antiplatelet Therapy (DAPT) Trial Which Was Published In The New England Journal of Medicine (Posted by Tom Lamb at DrugInjuryWatch.com)Plavix (clopidogrel) and…
-
Higher Doses Of Statin Drugs Such As Lipitor Associated With Higher Risk Of New-Onset Diabetes Mellitus (DM), Or Type-2 Diabetes
Recent Canadian Study Published In BMJ Medical Journal Suggests The Increased Risk Of Diabetes Seems To Be Highest In The First Four Months Of Statin Use (Posted by Tom Lamb at DrugInjuryWatch.com)According to the Parke-Davis,…
-
Blood Thinner Pradaxa Linked To More Cases Of Serious Bleeding Events And New FDA Study Confirms Increased Risk Of GI Bleeds Compared To Warfarin
More Than 2000 Pradaxa Lawsuits Have Been Filed Against Boehringer, And A Company Official Has Admitted That More Than 1400 Patients Bled To Death (Posted by Tom Lamb at DrugInjuryWatch.com)______________________________________________________________________________ UPDATE: Boehringer Pays $650 Million…
-
Depakote Or Depakene Taken During Pregnancy May Cause Congenital Malformations Or Birth Defects Such As Neural Tube Defects Like Spina Bifida
In Addition, There Are FDA Warnings That Using Depakote Or Depakene While Pregnant May Put Child At Risk For Having A Lower IQ Score Later In Life (Posted by Tom Lamb at DrugInjuryWatch.com) Depakote…
-
Fate Of Affymax Anemia Drug Omontys Remains Uncertain As FDA And Drug Company Continue To Study Cause Of Drug Reactions
Fresenius Dialysis Clinics Decided To Stop Using Omontys Before FDA Warning Came Out Due To Five Adverse Event Reports From One Day In February 2013 (Posted by Tom Lamb at DrugInjuryWatch.com)The Omontys (peginesatide) injection had…